Veritas myGenome: the clinician-mediated preventive WGS, with the prescription wall
Veritas Genetics pioneered the $999 consumer genome in 2016 and cut to $599 in 2019. After an operational pause in the US that same year — widely reported but less widely explained — the company returned with a restructured product. The Spring 2026 version of myGenome is, in the clearest sense available, not a consumer product at all: it's a preventive-medicine service delivered through a clinician-mediated workflow at consumer-ish pricing.
The product itself: $599 for a 30× whole genome on Illumina in a CLIA-certified lab, with a pre-test genetic counselor session AND a post-test genetic counselor session both included in the price. Turnaround is 12 to 16 weeks, longer than most competitors. The report is clinician-reviewed and formatted for a clinician audience — it reads less like a consumer app and more like a lab result. For a reader who plans to hand it to a physician, that is a feature, not a bug.
The counselor-mediated framing is the thing that differentiates Veritas from every other company on our leaderboard. The pre-test session grounds expectations: what the test can and can't tell you, what findings you might want to receive or decline, what you'd do with an ACMG-actionable result. The post-test session walks through findings in context — which is exactly what the rest of the category doesn't do, and exactly the thing that turns a raw list of variants into something a clinician can act on. This isn't upsell theater. For a reader with a family history of a specific condition it is the single most useful part of the purchase.
The prescription wall is real. As of early 2025, myGenome requires a prescription to order, and Veritas provides one through its own telegenetics consult if your primary-care doctor won't. We'd guess most first-time buyers route through the Veritas consult rather than their own PCP, and the extra step — plus the 12-to-16 week turnaround — filters out casual shoppers. That's either a strength or a weakness depending on what you want from the product.
What Veritas gets wrong: the consumer UI is a decade behind Nucleus. Report delivery is slow by modern standards. The prescription gate will turn away casual buyers who would genuinely benefit from the clinical framing — because the people who most need a clinician's perspective are often the ones least likely to jump through telegenetics hoops to get it.
The honest recommendation: if you or someone in your family has a specific clinical question — a family history of cardiomyopathy, a suspicion of a carrier-status issue ahead of family planning, an existing diagnosis you want to understand at the variant level — Veritas is the right product. Pay the premium, go through the prescription step, use both counselors. The product is priced and timed for readers who are going to actually engage with the clinical process, which is the right way to buy a $599 genome in April 2026.